Agreements and Contracts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Agreements and Contracts

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 2

The latest pacts from the pharmaceutical supply chain.

Princeton, NJ (Feb. 6) Laureate Pharma, Inc. ( http://www.laureatepharma.com/) formed a partnership with Boehringer Ingelheim (Ingelheim, Germany, http://www.boehringer-ingelheim.com/). The partnership gives Laureate's clients access to Boehringer's manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture. Clients also will have access to large-scale commercial production by Boehringer at its facility in Biberach, Germany.

Keele, UK (Feb. 1)-Cobra Biomanufacturing Plc ( http://www.cobrabio.com/) formed an agreement with Pharmexa (HØrsholm, Denmark, http://www.pharmexa.com/) for the manufacture of "PX107" protein vaccine for use in Phase I clinical trials for bone disorders. Cobra will manufacture the protein, and Pharmexa will carry out upstream and downstream development of the vaccine.

Gaithersburg, MD (Feb. 1)- GenVec, Inc. ( http://www.genvec.com/) signed a three-year contract with the Department of Homeland Security (DHS, Washington, DC, http://www.dhs.gov/) to develop and manufacture vaccines against foot and mouth disease. GenVec will receive as much as $6 million in program funding the first year and as much as $15 million over three years if DHS exercises its annual renewal options under the contract. GenVec will be responsible for the development, production, and regulatory approval of the vaccine, while DHS will conduct animal studies.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here